Principal Investigator,Professor : Group of vaccine design and antibody engineering

Yan Jinghua
Address:NO.1 West Beichen Road, Chaoyang District, Beijing 100101, China
Research Interests
The emerging infectious diseases have enormous effect on human health, social and economic wellbeing. It is signified in recent outbreaks of SARS-CoV-2 in the world, Zika virus in Latin America, Ebola virus in West Africa that devastated large communities around the world. Our research focuses on novel vaccines design and antibody drug development to defense virus attack. We analyze the structure of antigen and detect its interaction with antibodies. Through this strategy, we can maximize the availability of antigen epitopes and improve the immunogenicity of vaccines. Furthermore, we also interested in screening human antibodies against infectious diseases or tumors, analyzing the mechanism of antibody, and developing novel antibody drugs.
1982-1986 B.S. Biology Science, Anhui Normal University 1986-1989 M.S. Biochemistry, Nanjing Agricultural University 2001-2004 Ph.D Molecular Genetics, Institute of Beijing Biotechnology
Work experience
Professional Appointments 1999 Advanced Studies, Hanover University, Germany 1989-2001 Associate Professor, Anhui Agricultural University, China 2004-2012 Associate Professor, IMCAS, China 2012-now Professor, IMCAS, China Social Appointments Chinese Science Bulletin (Editorial Board member) Biosafety and Health (Editorial Board member) Journal of Genetics and Genomics (Editorial Board member) Antibody Professional Committee, Chinese Society of Bioengineering (committee member)
2014 The national science and technology progress award, China 2016 Top ten progress awards in life sciences, China 2017 Science and Technology award of China Preventive Medicine Association 2019 Group Award of Qiushi Outstanding Scientific and Technological Achievement 2020 Director's Fellowship Award for Excellence, Institute of Microbiology, Chinese Academy of Sciences 2020 National innovation Competition award, China
The main research areas
Structure-based novel vaccines design and antibody drug development
1. Tian S, Ji K, Wang M, Wang F, Wang H, Huang W*, Huang Q*, Yan J*, Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice, Cell Discovery 7(1) (2021) 91. 
2. Dai L, Xu K, Li J, Huang Q, Song J, Han Y, Zheng T, Gao P, Lu X, Yang H, Liu K, Xia Q, Wang Q, Chai Y, Qi J, Yan J*, Gao GF*. Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nature Immunology. 2021 Aug;22(8):958-968. 
3. Y Du, R. Shi, Y Zhang, X Duan, L Li, J Zhang, F Wang, R Zhang, H Shen, Y Wang, Z Wu, Q Peng, T Pan, W Sun, W Huang, Y Feng, H Feng, J Xiao, W Tan*, Y Wang*, C Wang*, J. Yan*, A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants, Nature Communications. 12(1) (2021) 5000. 
4. Huang Q, Ji K, Tian S, Wang F, Huang B, Tong Z, Tan S, Hao J, Wang Q, Tan W*, Gao G.F*, Yan J*. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2. Nature Communication. 2021, 12(1): 776. 
1. Shi R, Shan C; Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu W, Wu G, Zhang B, Wang L, Qi J, Feng H, Fu-S*, Wang Q*, Gao GF*, Yuan Z*, Yan J*. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020, 584:120-124. 
2. Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C*, Yan J*; Gao, GF*. A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS. Cell. 2020, 182 (3): 722-733. 
3. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K, Wang Q, Zhou H, Yan J*, Qi J*. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020, 181:894-904. 
4. Wu L, Chen Q, Liu K, Wang J, Han P, Zhang Y, Meng Y, Hu Y, Pan X, Qiao C, Tian S, Du P, Song H, Shi W, Qi J, Wang H*, Yan J*, Gao GF*, Wang Q*. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell discovery. 2020, 6: 68. 
5. Shi R, Chai Y, Duan X, Bi X, Huang Q, Wang Q, Tan S, Gao GF, Zhu J*, Yan J*. The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination. Signal Transduction and Targeted Therapy. 2020, 5(1):16. 
6. Liu H, Bi X, Zhou Y, Shi R, Yao S, Qi J, Feng H, Feng M*, Yan J*, Tan S*. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy. Signal Transduction and Targeted Therapy. 2020, 5(1):158. 
7. Su C, Wu L, Chai Y, Qi J, Tan S, Gao GF*, Song H*, Yan J*. Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses. Nature Communications, 2020, 11:5964. 
1. Chen D, Tan S, Zhang H, Wang H, He W, Shi R, Tong Z, Zhu J, Cheng H, Gao S, Chai Y, Qi J, Xiao M, Yan J*, Gao GF*. The FG Loop of PD-1 Serves as a ‘‘Hotspot’’ for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. iscience. 2019, 14:113-124. 
2. Wang Q, Ma T, Wu Y, Chen Z, Zeng H, Tong Z, Gao F, Qi J, Zhao Z, Chai Y, Yang H, Wong G, Bi Y, Wu L, Shi R, Yang M, Song J, Jiang H, An Z, Wang J, Yilma TD, Shi Y, Liu WJ, Liang M, Qin C, Gao GF*, Yan J*. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nature Microbiology. 2019, 4(7):1231-1241 
3. Liu H, Guo L, Zhang J, Zhou Y, Zhou J, Yao J, Wu H, Yao S, Chen B, Chai Y, Qi J, Gao GF, Tan S*, Feng H*, Yan J*. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs. 2019, 11(4):681-690.